Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Current Investments: 2020-2024

Historic Cash & Current Investments for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $257.9 million.

  • Tango Therapeutics' Cash & Current Investments fell 47.90% to $152.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $808.2 million, marking a year-over-year decrease of 37.79%. This contributed to the annual value of $257.9 million for FY2024, which is 24.21% down from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' Cash & Current Investments is $257.9 million, which was down 24.21% from $340.3 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Cash & Current Investments registered a high of $487.5 million during FY2021, and its lowest value of $192.6 million during FY2020.
  • Moreover, its 3-year median value for Cash & Current Investments was $340.3 million (2023), whereas its average is $321.5 million.
  • Per our database at Business Quant, Tango Therapeutics' Cash & Current Investments skyrocketed by 153.13% in 2021 and then fell by 24.90% in 2022.
  • Tango Therapeutics' Cash & Current Investments (Yearly) stood at $192.6 million in 2020, then soared by 153.13% to $487.5 million in 2021, then dropped by 24.90% to $366.1 million in 2022, then fell by 7.05% to $340.3 million in 2023, then decreased by 24.21% to $257.9 million in 2024.